Tendler S, Dunphy MP, Agee M, O'Donoghue J, et al. Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. Lancet Oncol 2024;25:1015-1024.
PMID: 38950555